BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaler C, Dollar J, Cruz A, Kuznetsoff J, Sanchez M, Decatur C, Licht J, Smalley K, Correa Z, Kurtenbach S, Harbour J. BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas. Cancers 2022;14:3678. [DOI: 10.3390/cancers14153678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Wu N, Feng X, Liang Y, Huang M, Li W, Hou L, Yin C. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma. Front Immunol 2022;13:1052692. [PMID: 36685506 DOI: 10.3389/fimmu.2022.1052692] [Reference Citation Analysis]
2 Glinkina K, Nemati F, Teunisse AFAS, Gelmi MC, Etienne V, Kuipers MJ, Alsafadi S, Jager MJ, Decaudin D, Jochemsen AG. Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci 2022;63:14. [PMID: 36515935 DOI: 10.1167/iovs.63.13.14] [Reference Citation Analysis]
3 Chatziioannou E, Aydin SA, Forchhammer S, Sinnberg T, Eigentler T. Makrophagen im Melanom – von molekularen Signalen zur therapeutischen Anwendung. Dermatologie 2022. [DOI: 10.1007/s00105-022-05077-3] [Reference Citation Analysis]
4 Setlai BP, Mkhize-Kwitshana ZL, Mehrotra R, Mulaudzi TV, Dlamini Z. Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma. Int J Mol Sci 2022;23:8991. [PMID: 36012262 DOI: 10.3390/ijms23168991] [Reference Citation Analysis]